Amylin Stock Is Pummeled At Diabetes Meeting

There was an 8 percent drop on Friday after Novo Nordisk presented data showing its once-a-day experimental med outperformed Amylin’s twice-a-day, Byetta flagship. Now, Amylin sunk another 10 percent after Roche released data at the American Diabetes Association meeting that poses yet another threat to both Byetta and a longer-lasting, follow-up drug. Both the Novo and Roche drugs are “viable” candidates, according to Cowen analyst Phil Nadeau, the Associated Press writes. As a result, competi